publication venue for
- The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer: A RADICAL-PC Analysis. 2023
- Cardiovascular Risk in Prostate Cancer: JACC: CardioOncology State-of-the-Art Review. 6:835-846. 2024
- Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes.. 6:761-771. 2024
- Assessing the Certainty of Evidence on Efficacy and Safety of Anticoagulants for Cancer-Associated Thrombosis. 6:622-623. 2024
- Dexrazoxane to Prevent Cardiotoxicity in Adults Treated with Anthracyclines. 6:322-324. 2024
- Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer. 6:117-129. 2024
- High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population. 6:136-138. 2024
- Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations 2024
- Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer. 5:613-624. 2023
- Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies. 5:415-430. 2023
- Reply. 5:552-552. 2023
- Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients. 5:201-202. 2023
- The Burden of Uncontrolled Cardiovascular Risk Factors in Men With Prostate Cancer. 5:70-81. 2023
- The European Society of Cardiology Cardio-Oncology Guidelines. 5:137-140. 2023
- Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer. 4:351-353. 2022
- What Cardio-Oncology Lessons Can We Learn From Population-Based Data?. 4:110-112. 2022
- Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors. 2:690-706. 2020
- Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity. 1:1-10. 2019